ELECTROCORE INC (ECOR) Stock Price & Overview
NASDAQ:ECOR • US28531P2020
The current stock price of ECOR is 6.85 USD. Today ECOR is down by -8.91%. In the past month the price increased by 35.11%. In the past year, price decreased by -51.42%.
ECOR Key Statistics
- Market Cap
- 54.8M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.71
- Dividend Yield
- N/A
ECOR Stock Performance
ECOR Stock Chart
ECOR Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ECOR. When comparing the yearly performance of all stocks, ECOR is a bad performer in the overall market: 72.71% of all stocks are doing better.
ECOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ECOR. ECOR may be in some trouble as it scores bad on both profitability and health.
ECOR Earnings
On November 5, 2025 ECOR reported an EPS of -0.4 and a revenue of 8.69M. The company beat EPS expectations (1.14% surprise) and beat revenue expectations (8.61% surprise).
ECOR Forecast & Estimates
11 analysts have analysed ECOR and the average price target is 20.07 USD. This implies a price increase of 193.05% is expected in the next year compared to the current price of 6.85.
For the next year, analysts expect an EPS growth of -9.59% and a revenue growth 26.73% for ECOR
ECOR Groups
Sector & Classification
ECOR Financial Highlights
Over the last trailing twelve months ECOR reported a non-GAAP Earnings per Share(EPS) of -1.71. The EPS increased by 6.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ECOR Ownership
ECOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.07 | 190.38B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.96 | 174.071B | ||
| SYK | STRYKER CORP | 24.1 | 139.513B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.4 | 105.876B | ||
| IDXX | IDEXX LABORATORIES INC | 41.04 | 48.442B | ||
| BDX | BECTON DICKINSON AND CO | 12.26 | 47.586B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.46 | 47.376B | ||
| RMD | RESMED INC | 20.59 | 36.838B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.37 | 33.849B | ||
| DXCM | DEXCOM INC | 26.79 | 26.209B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.1 | 18.413B | ||
| HOLX | HOLOGIC INC | 15.43 | 16.908B | ||
| PODD | INSULET CORP | 36.66 | 16.686B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ECOR
Company Profile
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Company Info
ELECTROCORE INC
200 Forge Way, Suite 205
Rockaway NEW JERSEY 07866 US
CEO: Daniel S. Goldberger
Employees: 73
Phone: 19732900097
ELECTROCORE INC / ECOR FAQ
What does ECOR do?
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 73 full-time employees. The company went IPO on 2018-06-22. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Can you provide the latest stock price for ELECTROCORE INC?
The current stock price of ECOR is 6.85 USD. The price decreased by -8.91% in the last trading session.
What is the dividend status of ELECTROCORE INC?
ECOR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ECOR stock?
ECOR has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ECOR stock?
ECOR stock is listed on the Nasdaq exchange.
How is the valuation of ELECTROCORE INC (ECOR) based on its PE ratio?
ELECTROCORE INC (ECOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.71).